Specifically, using a tetracycline-inducible system to activate TTP expression in metastatic PC-3 prostate cancer cells that express low levels of endogenous TTP, we found that TTP blocks proliferation and provokes cell cycle arrest ex vivo and impairs tumorigenicity in vivo. Here, ZFP36 is linked to prostate cancer.